#United States #New York #Securities Law #Faruqi & Faruqi #POMDOCTOR

Important Action Reminder for Pomdoctor Investors

Faruqi & Faruqi, LLP, a prominent national securities law firm, is reaching out to investors of Pomdoctor Limited (NASDAQ: POM) regarding important developments in a looming legal situation. Investors who purchased or acquired shares in Pomdoctor between October 9, 2025, and December 11, 2025, should take note of pending actions they might need to consider. The firm is specifically reminding these investors about the upcoming deadline of April 6, 2026, to become a lead plaintiff in a recently filed federal securities class action against the company.

The investigations spearheaded by Faruqi & Faruqi center on allegations that Pomdoctor and its executives may have violated federal securities laws. Key points of the complaint suggest a series of misleading statements made by the company's leadership. Notably, it is alleged that Pomdoctor was embroiled in a fraudulent stock promotion scheme which involved misinformation disseminated through social media and impersonation of credible financial professionals. Furthermore, troubling patterns have emerged indicating that insiders may have used offshore or nominee accounts during a phase of coordinated share dumping amidst a fraudulent price inflation campaign.

This expansion of investigation remains vital for shareholders, especially following a notable drop in Pomdoctor's share price between December 10 and December 11, 2025, where stock fell from approximately $0.50 to about $0.38, reflecting a staggering decline of around 24% in just one trading session. This fluctuation was exacerbated by rising concerns among investors regarding the company's financial integrity and its overall market valuation.

Should you hold shares of Pomdoctor and are wondering about your rights and potential for recovery, it is crucial to contact Josh Wilson—Senior Partner at Faruqi & Faruqi—directly at either 877-247-4292 or 212-983-9330 (Ext. 1310). The firm underscores that becoming a lead plaintiff is an important role for any investor with the most significant financial interest in the class and one who can guide the course of litigation in favor of the interests of all shareholders.

Additionally, potential class members have the option to choose whether or not to pursue lead plaintiff status. Rest assured, your eligibility for any financial recovery is not diminished based on your decision regarding lead plaintiff participation.

Faruqi & Faruqi further encourages anyone who possesses pertinent information related to Pomdoctor’s practices to come forward, especially whistleblowers, former employees, or other shareholders. Sharing insights regarding the company’s operations or any relevant conduct could be highly beneficial in the shaping of this case.

In conclusion, investing can be fraught with uncertainties, but timely and informed actions can cushion the impact of potential losses. Pomdoctor's shareholders would do well to seek guidance about their circumstances before this crucial deadline draws near. For continued updates and more comprehensive coverage of this class action, you can visit the Faruqi & Faruqi website or follow them on social media platforms like LinkedIn and Facebook. Remember, knowledge is power, especially in legal matters surrounding investments.

Please bear in mind that all communications will be handled with the utmost confidentiality, ensuring that your privacy and interests are prioritized throughout this process. For further inquiries or clarifications regarding this situation, do not hesitate to reach out.